Trial Profile

MEDI4736 combinations in metastatic renal cell carcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Savolitinib (Primary) ; Tremelimumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms CALYPSO

Most Recent Events

01 Aug 2026 Primary endpoint(To explore if KIM-1 levels were raised in pRCC) has been met.
01 Aug 2026 Results assessing durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC, published in the European Urology.
04 Nov 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com